Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

被引：0
|
作者：
Lowell L. Hart
Renata Ferrarotto
Zoran G. Andric
J. Thaddeus Beck
Janakiraman Subramanian
Davorin Z. Radosavljevic
Bojan Zaric
Wahid T. Hanna
Raid Aljumaily
Taofeek K. Owonikoko
Didier Verhoeven
Jie Xiao
Shannon R. Morris
Joyce M. Antal
Maen A. Hussein
机构：
[1] Florida Cancer Specialists,Medical Oncology
[2] Wake Forest University School of Medicine,Department of Medicine
[3] University of Texas MD Anderson Cancer Center,Department of Thoracic and Head and Neck Medical Oncology
[4] Clinical Hospital Center Bezanijska Kosa,Medical Oncology Department
[5] Department of Medical Oncology and Hematology,Department of Medicine
[6] Highlands Oncology Group,Faculty of Medicine, Institute for Pulmonary Diseases of Vojvodina
[7] Saint Luke’s Hospital,Hematology/Oncology
[8] Institute for Oncology and Radiology of Serbia,Stephenson Cancer Center
[9] University of Novi Sad,Department of Hematology and Medical Oncology
[10] University of Tennessee Graduate School of Medicine,Department of Medical Oncology, AZ Klina Brasschaat
[11] University of Oklahoma,Department of Oncology
[12] Sarah Cannon Research Institute,undefined
[13] Emory University,undefined
[14] University of Antwerp,undefined
[15] G1 Therapeutics,undefined
[16] Inc.,undefined
[17] Florida Cancer Specialists,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Anemia; Chemotherapy; Myelopreservation; Myelosuppression; Neutropenia; Patient-reported outcomes; Small cell lung cancer; Topotecan; Trilaciclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：350 / 365
页数：15
相关论文
共 50 条
  • [1] Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
    Hart, Lowell L.
    Ferrarotto, Renata
    Andric, Zoran G.
    Beck, J. Thaddeus
    Subramanian, Janakiraman
    Radosavljevic, Davorin Z.
    Zaric, Bojan
    Hanna, Wahid T.
    Aljumaily, Raid
    Owonikoko, Taofeek K.
    Verhoeven, Didier
    Xiao, Jie
    Morris, Shannon R.
    Antal, Joyce M.
    Hussein, Maen A.
    ADVANCES IN THERAPY, 2021, 38 (01) : 350 - 365
  • [2] Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)
    Cheng, Ying
    Wu, Lin
    Huang, Dingzhi
    Wang, QiMing
    Fan, Yun
    Zhang, XiQin
    Fan, HuiJie
    Yao, WenXiu
    Liu, BaoGang
    Yu, GuoHua
    Pan, YueYin
    Xu, Fei
    He, ZhiYong
    Dong, XiaoRong
    Ma, Rui
    Min, XuHong
    Ge, XiaoSong
    Chen, Hualin
    Liu, Qun
    Hu, YanPing
    Liu, Ying
    Yang, Chen
    Yang, Yang
    Li, Xiucui
    Zhou, Li
    LUNG CANCER, 2024, 188
  • [3] Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
    Volovat, Constantin
    Bondarenko, Igor M.
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    SPRINGERPLUS, 2015, 4
  • [4] Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    Vansteenkiste, J
    Pirker, R
    Massuti, B
    Barata, F
    Font, A
    Fiegl, M
    Siena, S
    Gateley, J
    Tomita, D
    Colowick, AB
    Musil, J
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (16) : 1211 - 1220
  • [5] Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled study
    Papp, K
    Mease, P
    Garovoy, M
    Zhang, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [6] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [7] Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
    Hussein, Maen
    Maglakelidze, Marina
    Richards, Donald A.
    Sabatini, Marielle
    Gersten, Todd A.
    Lerro, Keith
    Sinielnikov, Ivan
    Spira, Alexander
    Pritchett, Yili
    Malik, Rajesh
    Beck, J. Thaddeus
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6207 - 6218
  • [8] Melatonin in Patients with Cancer Receiving Chemotherapy: A Randomized, Double-blind, Placebo-controlled Trial
    Sookprasert, Aumkhae
    Johns, Nutjaree Pratheepawanit
    Phunmanee, Anakapong
    Pongthai, Parichart
    Cheawchanwattana, Areewan
    Johns, Jeff
    Konsil, Julraht
    Plaimee, Preeyaporn
    Porasuphatana, Supatra
    Jitpimolmard, Suthiphan
    ANTICANCER RESEARCH, 2014, 34 (12) : 7327 - 7337
  • [9] Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
    Daniel, Davey
    Kuchava, Vladimer
    Bondarenko, Igor
    Ivashchuk, Oleksandr
    Reddy, Sreekanth
    Jaal, Jana
    Kudaba, Iveta
    Hart, Lowell
    Matitashvili, Amiran
    Pritchett, Yili
    Morris, Shannon R.
    Sorrentino, Jessica A.
    Antal, Joyce M.
    Goldschmidt, Jerome
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (10) : 2557 - 2570
  • [10] Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy
    Glaspy, J. A.
    Smith, R. E.
    Aapro, M.
    Ludwig, H.
    Pinter, T.
    Smakal, M.
    Ciuleanu, T.
    Chen, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 136 - 136
12345